Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

PAR vs RLAY vs TOST vs KYMR

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
PAR
PAR Technology Corporation

Software - Application

TechnologyNYSE • US
Market Cap$617M
5Y Perf.-75.7%
RLAY
Relay Therapeutics, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$2.37B
5Y Perf.-60.3%
TOST
Toast, Inc.

Software - Infrastructure

TechnologyNYSE • US
Market Cap$17.02B
5Y Perf.-41.2%
KYMR
Kymera Therapeutics, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$6.91B
5Y Perf.+44.1%

PAR vs RLAY vs TOST vs KYMR — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
PAR logoPAR
RLAY logoRLAY
TOST logoTOST
KYMR logoKYMR
IndustrySoftware - ApplicationBiotechnologySoftware - InfrastructureBiotechnology
Market Cap$617M$2.37B$17.02B$6.91B
Revenue (TTM)$476M$11M$6.45B$51M
Net Income (TTM)$-76M$-273M$412M$-315M
Gross Margin40.1%66.3%26.2%33.2%
Operating Margin-13.5%-27.8%5.6%-7.0%
Forward P/E28.3x23.7x
Total Debt$402M$32M$40M$82M
Cash & Equiv.$80M$84M$1.35B$357M

PAR vs RLAY vs TOST vs KYMRLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

PAR
RLAY
TOST
KYMR
StockSep 21May 26Return
PAR Technology Corp… (PAR)10024.3-75.7%
Relay Therapeutics,… (RLAY)10039.7-60.3%
Toast, Inc. (TOST)10058.8-41.2%
Kymera Therapeutics… (KYMR)100144.1+44.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: PAR vs RLAY vs TOST vs KYMR

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: TOST leads in 3 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Relay Therapeutics, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. KYMR also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
PAR
PAR Technology Corporation
The Growth Angle

PAR lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: technology exposure
RLAY
Relay Therapeutics, Inc.
The Growth Play

RLAY is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 53.4%, EPS growth 31.8%, 3Y rev CAGR 123.2%
  • 53.4% revenue growth vs KYMR's -16.7%
  • +324.1% vs PAR's -75.6%
Best for: growth exposure
TOST
Toast, Inc.
The Value Play

TOST carries the broadest edge in this set and is the clearest fit for value and quality.

  • Better valuation composite
  • 6.4% margin vs RLAY's -25.5%
  • 13.8% ROA vs RLAY's -40.1%, ROIC 30.8% vs -37.3%
Best for: value and quality
KYMR
Kymera Therapeutics, Inc.
The Income Pick

KYMR is the clearest fit if your priority is income & stability and long-term compounding.

  • beta 1.15
  • 154.4% 10Y total return vs PAR's 167.3%
  • Lower volatility, beta 1.15, Low D/E 5.2%, current ratio 10.47x
  • Beta 1.15, current ratio 10.47x
Best for: income & stability and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthRLAY logoRLAY53.4% revenue growth vs KYMR's -16.7%
ValueTOST logoTOSTBetter valuation composite
Quality / MarginsTOST logoTOST6.4% margin vs RLAY's -25.5%
Stability / SafetyKYMR logoKYMRBeta 1.15 vs RLAY's 1.77, lower leverage
DividendsTieNone of these 4 stocks pay a meaningful dividend
Momentum (1Y)RLAY logoRLAY+324.1% vs PAR's -75.6%
Efficiency (ROA)TOST logoTOST13.8% ROA vs RLAY's -40.1%, ROIC 30.8% vs -37.3%

PAR vs RLAY vs TOST vs KYMR — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

PARPAR Technology Corporation
FY 2025
Subscription Service
63.9%$291M
Hardware
23.4%$106M
Professional Service
12.7%$58M
RLAYRelay Therapeutics, Inc.

Segment breakdown not available.

TOSTToast, Inc.
FY 2025
Technology Service
84.3%$5.0B
License
15.7%$936M
KYMRKymera Therapeutics, Inc.

Segment breakdown not available.

PAR vs RLAY vs TOST vs KYMR — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLTOSTLAGGINGRLAY

Income & Cash Flow (Last 12 Months)

TOST leads this category, winning 4 of 6 comparable metrics.

TOST is the larger business by revenue, generating $6.4B annually — 603.7x RLAY's $11M. TOST is the more profitable business, keeping 6.4% of every revenue dollar as net income compared to RLAY's -25.5%. On growth, KYMR holds the edge at +55.5% YoY revenue growth, suggesting stronger near-term business momentum.

MetricPAR logoPARPAR Technology Co…RLAY logoRLAYRelay Therapeutic…TOST logoTOSTToast, Inc.KYMR logoKYMRKymera Therapeuti…
RevenueTrailing 12 months$476M$11M$6.4B$51M
EBITDAEarnings before interest/tax-$27M-$298M$409M-$352M
Net IncomeAfter-tax profit-$76M-$273M$412M-$315M
Free Cash FlowCash after capex-$29M-$213M$654M-$244M
Gross MarginGross profit ÷ Revenue+40.1%+66.3%+26.2%+33.2%
Operating MarginEBIT ÷ Revenue-13.5%-27.8%+5.6%-7.0%
Net MarginNet income ÷ Revenue-16.0%-25.5%+6.4%-6.1%
FCF MarginFCF ÷ Revenue-6.0%-20.0%+10.1%-4.7%
Rev. Growth (YoY)Latest quarter vs prior year+19.4%-60.9%+21.9%+55.5%
EPS Growth (YoY)Latest quarter vs prior year+36.1%+10.9%+127.5%+13.4%
TOST leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

PAR leads this category, winning 2 of 4 comparable metrics.
MetricPAR logoPARPAR Technology Co…RLAY logoRLAYRelay Therapeutic…TOST logoTOSTToast, Inc.KYMR logoKYMRKymera Therapeuti…
Market CapShares × price$617M$2.4B$17.0B$6.9B
Enterprise ValueMkt cap + debt − cash$940M$2.3B$15.7B$6.6B
Trailing P/EPrice ÷ TTM EPS-7.16x-7.77x52.43x-22.93x
Forward P/EPrice ÷ next-FY EPS est.28.32x23.69x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple42.22x
Price / SalesMarket cap ÷ Revenue1.36x154.15x2.77x176.26x
Price / BookPrice ÷ Book value/share0.73x3.79x8.39x4.52x
Price / FCFMarket cap ÷ FCF27.99x
PAR leads this category, winning 2 of 4 comparable metrics.

Profitability & Efficiency

TOST leads this category, winning 7 of 9 comparable metrics.

TOST delivers a 20.7% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $-44 for RLAY. TOST carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to PAR's 0.49x. On the Piotroski fundamental quality scale (0–9), TOST scores 7/9 vs PAR's 2/9, reflecting strong financial health.

MetricPAR logoPARPAR Technology Co…RLAY logoRLAYRelay Therapeutic…TOST logoTOSTToast, Inc.KYMR logoKYMRKymera Therapeuti…
ROE (TTM)Return on equity-9.1%-43.9%+20.7%-25.0%
ROA (TTM)Return on assets-5.5%-40.1%+13.8%-22.3%
ROICReturn on invested capital-4.2%-37.3%+30.8%-24.9%
ROCEReturn on capital employed-5.1%-42.7%+15.9%-27.2%
Piotroski ScoreFundamental quality 0–92574
Debt / EquityFinancial leverage0.49x0.06x0.02x0.05x
Net DebtTotal debt minus cash$323M-$52M-$1.3B-$275M
Cash & Equiv.Liquid assets$80M$84M$1.4B$357M
Total DebtShort + long-term debt$402M$32M$40M$82M
Interest CoverageEBIT ÷ Interest expense-21.71x-2119.53x
TOST leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

KYMR leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in KYMR five years ago would be worth $19,212 today (with dividends reinvested), compared to $1,914 for PAR. Over the past 12 months, RLAY leads with a +324.1% total return vs PAR's -75.6%. The 3-year compound annual growth rate (CAGR) favors KYMR at 45.0% vs PAR's -20.2% — a key indicator of consistent wealth creation.

MetricPAR logoPARPAR Technology Co…RLAY logoRLAYRelay Therapeutic…TOST logoTOSTToast, Inc.KYMR logoKYMRKymera Therapeuti…
YTD ReturnYear-to-date-58.1%+52.9%-13.7%+16.3%
1-Year ReturnPast 12 months-75.6%+324.1%-17.4%+190.7%
3-Year ReturnCumulative with dividends-49.2%+15.6%+51.7%+205.1%
5-Year ReturnCumulative with dividends-80.9%-57.6%-53.0%+92.1%
10-Year ReturnCumulative with dividends+167.3%-64.3%-53.0%+154.4%
CAGR (3Y)Annualised 3-year return-20.2%+5.0%+14.9%+45.0%
KYMR leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

KYMR leads this category, winning 2 of 2 comparable metrics.

KYMR is the less volatile stock with a 1.15 beta — it tends to amplify market swings less than RLAY's 1.77 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KYMR currently trades 82.2% from its 52-week high vs PAR's 20.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricPAR logoPARPAR Technology Co…RLAY logoRLAYRelay Therapeutic…TOST logoTOSTToast, Inc.KYMR logoKYMRKymera Therapeuti…
Beta (5Y)Sensitivity to S&P 5001.54x1.77x1.44x1.15x
52-Week HighHighest price in past year$72.15$17.31$49.66$103.00
52-Week LowLowest price in past year$11.59$2.67$24.35$28.06
% of 52W HighCurrent price vs 52-week peak+20.7%+72.3%+59.1%+82.2%
RSI (14)Momentum oscillator 0–10047.345.950.554.1
Avg Volume (50D)Average daily shares traded1.9M3.1M9.9M602K
KYMR leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: PAR as "Buy", RLAY as "Buy", TOST as "Buy", KYMR as "Buy". Consensus price targets imply 72.7% upside for RLAY (target: $22) vs 35.4% for TOST (target: $40).

MetricPAR logoPARPAR Technology Co…RLAY logoRLAYRelay Therapeutic…TOST logoTOSTToast, Inc.KYMR logoKYMRKymera Therapeuti…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$25.00$21.60$39.76$117.06
# AnalystsCovering analysts11152926
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises1
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap+1.1%0.0%+0.6%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

TOST leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). KYMR leads in 2 (Total Returns, Risk & Volatility).

Best OverallToast, Inc. (TOST)Leads 2 of 6 categories
Loading custom metrics...

PAR vs RLAY vs TOST vs KYMR: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is PAR or RLAY or TOST or KYMR a better buy right now?

For growth investors, Relay Therapeutics, Inc.

(RLAY) is the stronger pick with 53. 4% revenue growth year-over-year, versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). Toast, Inc. (TOST) offers the better valuation at 52. 4x trailing P/E (23. 7x forward), making it the more compelling value choice. Analysts rate PAR Technology Corporation (PAR) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — PAR or RLAY or TOST or KYMR?

On forward P/E, Toast, Inc.

is actually cheaper at 23. 7x.

03

Which is the better long-term investment — PAR or RLAY or TOST or KYMR?

Over the past 5 years, Kymera Therapeutics, Inc.

(KYMR) delivered a total return of +92. 1%, compared to -80. 9% for PAR Technology Corporation (PAR). Over 10 years, the gap is even starker: PAR returned +167. 3% versus RLAY's -64. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — PAR or RLAY or TOST or KYMR?

By beta (market sensitivity over 5 years), Kymera Therapeutics, Inc.

(KYMR) is the lower-risk stock at 1. 15β versus Relay Therapeutics, Inc. 's 1. 77β — meaning RLAY is approximately 54% more volatile than KYMR relative to the S&P 500. On balance sheet safety, Toast, Inc. (TOST) carries a lower debt/equity ratio of 2% versus 49% for PAR Technology Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — PAR or RLAY or TOST or KYMR?

By revenue growth (latest reported year), Relay Therapeutics, Inc.

(RLAY) is pulling ahead at 53. 4% versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). On earnings-per-share growth, the picture is similar: Toast, Inc. grew EPS 1639% year-over-year, compared to -1392. 9% for PAR Technology Corporation. Over a 3-year CAGR, RLAY leads at 123. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — PAR or RLAY or TOST or KYMR?

Toast, Inc.

(TOST) is the more profitable company, earning 5. 6% net margin versus -1800. 6% for Relay Therapeutics, Inc. — meaning it keeps 5. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TOST leads at 5. 0% versus -1971. 6% for RLAY. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is PAR or RLAY or TOST or KYMR more undervalued right now?

On forward earnings alone, Toast, Inc.

(TOST) trades at 23. 7x forward P/E versus 28. 3x for PAR Technology Corporation — 4. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RLAY: 72. 7% to $21. 60.

08

Which pays a better dividend — PAR or RLAY or TOST or KYMR?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is PAR or RLAY or TOST or KYMR better for a retirement portfolio?

For long-horizon retirement investors, Kymera Therapeutics, Inc.

(KYMR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15), +154. 4% 10Y return). Relay Therapeutics, Inc. (RLAY) carries a higher beta of 1. 77 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KYMR: +154. 4%, RLAY: -64. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between PAR and RLAY and TOST and KYMR?

These companies operate in different sectors (PAR (Technology) and RLAY (Healthcare) and TOST (Technology) and KYMR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: PAR is a small-cap high-growth stock; RLAY is a small-cap high-growth stock; TOST is a mid-cap high-growth stock; KYMR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

PAR

High-Growth Disruptor

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 9%
  • Gross Margin > 24%
Run This Screen
Stocks Like

RLAY

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 39%
Run This Screen
Stocks Like

TOST

High-Growth Disruptor

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 10%
  • Net Margin > 5%
Run This Screen
Stocks Like

KYMR

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 27%
  • Gross Margin > 19%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform PAR and RLAY and TOST and KYMR on the metrics below

Revenue Growth>
%
(PAR: 19.4% · RLAY: -60.9%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.